APC and colorectal carcinoma: The first commercially available GCN2 inhibitor A-92, a triazolo [4,5-d] pyrimidine derivative, reduces the viability of APC-deleted CRC cells as well as murine and patient-derived organoids (PDOs), however, it cannot be used in vivo [12].